drugset / Trial / NCT00584740
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-08
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “The study was terminated prematurely after futility criterion was met at planned interim analysis of 41 patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 10 mg/kg | Intravenous |